Lakefront Biotherapeutics American Depositary Shares LKFT
HEALTHCARE · BIOTECHNOLOGYi
Market dataready · fetched 2026-11-13T02:13:01.316Z
Delta surfaceAlpaca · derived absolute-delta buckets · 2026-12-18
Calculation methodologyOptions historyIV: ThetaData historical Greeks, equal-weight mean of call/put 50-delta IV across the next four listed Friday-cycle expirations, including holiday shifts verified against ThetaData’s market calendar. Missing inputs leave gaps. Skew: equal-weight mean of put minus call IV across those four expirations. IV-implied move history: mean of each expiration’s average call/put IV multiplied by the square root of remaining calendar days divided by 365.25; percentage of spot, not a quoted straddle premium.
History dataPriceAlpaca · sip · 2026-11-12T21:47:36.316854912Z
FundamentalsAlpha Vantage · ready · quarter 2026-06-30 · fetched 2026-11-13T02:05:57.515466+00:00
Lakefront Biotherapeutics American Depositary Shares options
Table
| Delta | Calls | Puts | ||||
|---|---|---|---|---|---|---|
| Pseudo strike | IV | B/E move | Pseudo strike | IV | B/E move | |
| 20Δ | 39.20 | 49.0% | 17.4% | |||
| 25Δ | 38.50 | 52.9% | 16.3% | |||
| 30Δ | 37.81 | 56.9% | 15.2% | 30.22 | 103.2% | 18.3% |
| 35Δ | 37.11 | 60.9% | 14.2% | 31.23 | 91.3% | 15.4% |
| 40Δ | 36.42 | 64.9% | 13.1% | 32.23 | 79.4% | 12.4% |
| 45Δ | 35.72 | 68.8% | 12.1% | 33.23 | 67.5% | 9.5% |
| 50Δ | 35.03 | 72.8% | 11.0% | 34.23 | 55.6% | 6.5% |
| 55Δ | 34.32 | 68.6% | 9.7% | |||
| 60Δ | 33.62 | 64.1% | 8.3% | |||
| 65Δ | 32.92 | 59.6% | 6.9% | |||
| 70Δ | 32.21 | 55.1% | 5.6% | |||
| 75Δ | 31.51 | 50.6% | 4.2% | |||
| 80Δ | 30.81 | 46.0% | 2.9% | |||
20Δ
- Pseudo strike
- 39.20
- IV
- 49.0%
- B/E move
- 17.4%
- Pseudo strike
- IV
- B/E move
25Δ
- Pseudo strike
- 38.50
- IV
- 52.9%
- B/E move
- 16.3%
- Pseudo strike
- IV
- B/E move
30Δ
- Pseudo strike
- 37.81
- IV
- 56.9%
- B/E move
- 15.2%
- Pseudo strike
- 30.22
- IV
- 103.2%
- B/E move
- 18.3%
35Δ
- Pseudo strike
- 37.11
- IV
- 60.9%
- B/E move
- 14.2%
- Pseudo strike
- 31.23
- IV
- 91.3%
- B/E move
- 15.4%
40Δ
- Pseudo strike
- 36.42
- IV
- 64.9%
- B/E move
- 13.1%
- Pseudo strike
- 32.23
- IV
- 79.4%
- B/E move
- 12.4%
45Δ
- Pseudo strike
- 35.72
- IV
- 68.8%
- B/E move
- 12.1%
- Pseudo strike
- 33.23
- IV
- 67.5%
- B/E move
- 9.5%
50Δ
- Pseudo strike
- 35.03
- IV
- 72.8%
- B/E move
- 11.0%
- Pseudo strike
- 34.23
- IV
- 55.6%
- B/E move
- 6.5%
55Δ
- Pseudo strike
- 34.32
- IV
- 68.6%
- B/E move
- 9.7%
- Pseudo strike
- IV
- B/E move
60Δ
- Pseudo strike
- 33.62
- IV
- 64.1%
- B/E move
- 8.3%
- Pseudo strike
- IV
- B/E move
65Δ
- Pseudo strike
- 32.92
- IV
- 59.6%
- B/E move
- 6.9%
- Pseudo strike
- IV
- B/E move
70Δ
- Pseudo strike
- 32.21
- IV
- 55.1%
- B/E move
- 5.6%
- Pseudo strike
- IV
- B/E move
75Δ
- Pseudo strike
- 31.51
- IV
- 50.6%
- B/E move
- 4.2%
- Pseudo strike
- IV
- B/E move
80Δ
- Pseudo strike
- 30.81
- IV
- 46.0%
- B/E move
- 2.9%
- Pseudo strike
- IV
- B/E move
Options history
Table
| Date | IV (%) |
|---|---|
| 49.40% | |
| 53.32% | |
| 48.34% | |
| 54.98% | |
| 58.17% | |
| 59.12% |
Biotechnology
LRMR
Larimar Therapeutics, Inc., a clinical-stage biotechnology company, is focused on developing treatments for rare diseases. The company is headquartered in Bala Cynwyd,…
More →LXEO
Lexeo Therapeutics, Inc. is a clinical stage genetic medicine company that focuses on hereditary and acquired diseases. The company is headquartered in New York, New York.
More →LXRX
Lexicon Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the discovery, development and commercialization of pharmaceutical products. The company is headquartered in…
More →LYEL
Lyell Immunopharma, Inc., a T-cell reprogramming company, is dedicated to the development of T-cell therapies for patients with solid tumors. The company is headquartered in South…
More →MANE
Veradermics, Incorporated is a biopharmaceutical company focused on developing novel therapeutics for dermatologic and aesthetic conditions. The company is headquartered in New…
More →MAZE
Maze Therapeutics, Inc., a clinical stage biopharmaceutical company, develops small molecule precision medicines for the treatment of renal, cardiovascular, related metabolic…
More →